Compile Data Set for Download or QSAR
Report error Found 44 Enz. Inhib. hit(s) with all data for entry = 2976
TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387238(US9938274, 4)
Affinity DataIC50: 0.390nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387238(US9938274, 4)
Affinity DataIC50: 2.07nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387257(BDBM50551459 | US9938274, Comparative Compound C)
Affinity DataIC50: 5.70nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387249(US9938274, 12)
Affinity DataIC50: 7.20nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387242(US9938274, 7)
Affinity DataIC50: 7.40nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387241(US9938274, 6)
Affinity DataIC50: 7.90nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387257(BDBM50551459 | US9938274, Comparative Compound C)
Affinity DataIC50: 8.5nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387250(US9938274, 13)
Affinity DataIC50: 9nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387239(US9938274, 5)
Affinity DataIC50: 9.40nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387248(US9938274, 11)
Affinity DataIC50: 9.5nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387242(US9938274, 7)
Affinity DataIC50: 10.2nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387258(US9938274, Comparative Compound D)
Affinity DataIC50: 12.1nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387245(US9938274, 10)
Affinity DataIC50: 12.7nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387244(US9938274, 9)
Affinity DataIC50: 13.3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387251(US9938274, 14)
Affinity DataIC50: 14.3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387253(US9938274, 16)
Affinity DataIC50: 14.4nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387236(US9938274, 2)
Affinity DataIC50: 15.6nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387243(US9938274, 8)
Affinity DataIC50: 16.8nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387235(US9938274, 1)
Affinity DataIC50: 19.4nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387237(US9938274, 3)
Affinity DataIC50: 20.1nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387252(US9938274, 15)
Affinity DataIC50: 22.4nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387244(US9938274, 9)
Affinity DataIC50: 28nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387236(US9938274, 2)
Affinity DataIC50: 28.4nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387239(US9938274, 5)
Affinity DataIC50: 29.5nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387241(US9938274, 6)
Affinity DataIC50: 31.2nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387243(US9938274, 8)
Affinity DataIC50: 36.4nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387254(US9938274, 17)
Affinity DataIC50: 40nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387255(US9938274, 18)
Affinity DataIC50: 40.3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387235(US9938274, 1)
Affinity DataIC50: 47.1nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387237(US9938274, 3)
Affinity DataIC50: 48.9nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387258(US9938274, Comparative Compound D)
Affinity DataIC50: 60nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387259(US9938274, Comparative Compound A)
Affinity DataIC50: 68.3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387259(US9938274, Comparative Compound A)
Affinity DataIC50: 125nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetHepatocyte growth factor receptor(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387260(US9938274, Comparative Compound B)
Affinity DataIC50: 143nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387260(US9938274, Comparative Compound B)
Affinity DataIC50: 182nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387252(US9938274, 15)
Affinity DataIC50: 5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387251(US9938274, 14)
Affinity DataIC50: 5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387254(US9938274, 17)
Affinity DataIC50: 5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387253(US9938274, 16)
Affinity DataIC50: 5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387248(US9938274, 11)
Affinity DataIC50: 5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387245(US9938274, 10)
Affinity DataIC50: 5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387255(US9938274, 18)
Affinity DataIC50: 5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387250(US9938274, 13)
Affinity DataIC50: 5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Nanjing Natinefy Pharmatech

US Patent
LigandPNGBDBM387249(US9938274, 12)
Affinity DataIC50: 5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
US Patent